15
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Bestrophin 1 and Retinal Disease

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Mutations in the gene BEST1 are causally associated with as many as five clinically distinct retinal degenerative diseases, which are collectively referred to as the “bestrophinopathies”. These five associated diseases are: Best vitelliform macular dystrophy, autosomal recessive bestrophinopathy, adult-onset vitelliform macular dystrophy, autosomal dominant vitreoretinochoroidopathy, and retinitis pigmentosa. The most common of these is Best vitelliform macular dystrophy. Bestrophin 1 (Best1), the protein encoded by the gene BEST1, has been the subject of a great deal of research since it was first identified nearly two decades ago. Today we know that Best1 functions as both a pentameric anion channel and a regulator of intracellular Ca 2+ signaling. Best1 is an integral membrane protein which, within the eye, is uniquely expressed in the retinal pigment epithelium where it predominantly localizes to the basolateral plasma membrane. Within the brain, Best1 expression has been documented in both glial cells and astrocytes where it functions in both tonic GABA release and glutamate transport. The crystal structure of Best1 has revealed critical information about how Best1 functions as an ion channel and how Ca 2+ regulates that function. Studies using animal models have led to critical insights into the physiological roles of Best1 and advances in stem cell technology have allowed for the development of patient-derived, “disease in a dish” models. In this article we review our knowledge of Best1 and discuss prospects for near-term clinical trials to test therapies for the bestrophinopathies, a currently incurable and untreatable set of diseases.

          Related collections

          Author and article information

          Journal
          9431859
          20937
          Prog Retin Eye Res
          Prog Retin Eye Res
          Progress in retinal and eye research
          1350-9462
          1873-1635
          8 February 2017
          30 January 2017
          May 2017
          01 May 2018
          : 58
          : 45-69
          Affiliations
          [1 ]Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota, USA
          [2 ]Nikon Instruments, Melville, New York, USA
          [3 ]Department of Clinical Studies-Philadelphia, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
          [4 ]Center for Neuroscience and Functional Connectomics, Brain Science Institute, Korea Institute of Science and Technology, Seoul, Korea
          [5 ]New York Structural Biology Center, New York Consortium on Membrane Protein Structure, New York, New York, USA
          Author notes
          [* ]Corresponding author: Alan D. Marmorstein, Department of Ophthalmology, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, Marmorstein.alan@ 123456mayo.edu , Phone: 507-284-2261
          Article
          PMC5600499 PMC5600499 5600499 nihpa849800
          10.1016/j.preteyeres.2017.01.006
          5600499
          28153808
          f6f9bca7-4385-4c29-a2de-bab8ef87371c
          History
          Categories
          Article

          anion channel,Bestrophin,Best1,retinal pigment epithelium,retinal disease,maculopathy

          Comments

          Comment on this article